Biomarker discovery using miRNA expression array in patients with ovarian cancer treated with dose-dense Paclitaxel combined with intraperitoneal chemotherapy of Carboplatin

• Project/Area Number: 24592527
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Saitama Medical University
• Principal Investigator: HASEGAWA Kosei 埼玉医科大学, 医学部, 准教授 (30534193)
• Co-Investigator(Kenkyū-buntansha): EGUCHI Hidetaka 埼玉医科大学, 医学部, 准教授 (00260232) ; WADA Satoshi 埼玉医科大学, 医学部, 助教 (80438837)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 卵巣癌 / マイクロRNA / 遺伝子発現 / バイオマーカー / 癌 / 遺伝子 / 発現制御

Outline of Final Research Achievements

We investigated the biomarker of ovarian cancer using the samples and clinical information of a phase II study of dose-dense Paclitaxel combined with intraperitoneal chemotherapy of Carboplatin (ddTCip). We performed miRNA array, and analyzed miRNA expression and its relationship with clinical information. We found decreased levels of miR-100, miR-126, and miR-145 expression in patients with PR or CR, which suggests potential predictive marker for ddTCip therapy. In addition, we observed increased levels of miR-142-3p and miR-28-5p expression in platinum resistant ovarian cancer patients. Confirmation and validation is warranted in on-foing phase III trial of ddTCip therapy (iPocc trial).

Research Products

• [Journal Article] The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients. (2015)
  • Author(s): Ikeda Y, Hasegawa K, Kurosaki A, Miyara A, Hanaoka T, Shintani D, Imai Y, Nishikawa T, Oda K, Fujiwara K.
  • Journal Title: Oncol Res Treat. Volume: 未
  • Peer Reviewed
• [Journal Article] Synchronous mucinous metaplasia and neoplasia of the female genital tract with external urethral meatus neoplasm: A case report. (2015)
  • Author(s): Ikeda Y, Yasuda M, Kato, T, Yano Y, Kurosaki A, Hasegawa K.
  • Journal Title: Gynecol Oncol Reports. Volume: online journalのためなし Pages: 27-30
  • DOI: 10.1016/j.gore.2015.02.001
  • Peer Reviewed / Open Access
• [Journal Article] Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. (2015)
  • Author(s): Matsuo K, Yoshino K, Hasegawa K, Murakami R, Ikeda Y, Adachi S, Hiramatsu K, Yokoyama T, Nishimura M, Sheridan TB, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Fotopoulou C, Roman LD, Sood AK.
  • Journal Title: Gynecol Oncol. Volume: 136 Issue: 2 Pages: 198-204
  • DOI: 10.1016/j.ygyno.2014.12.006
  • Peer Reviewed
• [Journal Article] A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors. (2015)
  • Author(s): Sasaki Y, Miwa K, Yamashita K, Sunakawa Y, Shimada K, Ishida H, Hasegawa K, Fujiwara K, Kodaira M, Fujiwara Y, Namiki M, Matsuda M, Takeuchi Y, Katsumata N.
  • Journal Title: Invest New Drugs. Volume: 33 Pages: 332-40
  • Peer Reviewed / Open Access
• [Journal Article] Impact of molecular classification on clinical management of ovarian cancer (2015)
  • Author(s): Hasegawa K
  • Journal Title: Gan to Kagaku Ryoho Volume: 42 Pages: 166-8
• [Journal Article] Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. (2014)
  • Author(s): Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K.
  • Journal Title: Int J Gynecol Cancer. Volume: 24 Issue: Supp 3 Pages: 90-5
  • DOI: 10.1097/igc.0000000000000297
  • Peer Reviewed
• [Journal Article] Feasibility Study of Combination Chemotherapy with Paclitaxel, Doxorubicin and Cisplatin without Prophylactic Granulocyte Colony-stimulating Factor Injection for Intermediate-to-high risk or Recurrent Endometrial Cancer. (2014)
  • Author(s): Nagao S, Nishikawa T, Hanaoka T, Kurosaki A, Iwasa N, Hasegawa K, Fujiwara K.
  • Journal Title: Jpn J Clin Oncol. Volume: 44 Issue: 11 Pages: 1040-4
  • DOI: 10.1093/jjco/hyu124
  • Peer Reviewed / Open Access
• [Journal Article] Development, Optimization, and Validation of Novel anti-TEM1/CD248 Affinity Agent for Optical Imaging in Cancer. (2014)
  • Author(s): Li C, Wang J, Hu J, Feng Y, Hasegawa K, Peng X, Duan X, Zhao A, Mikitsh J, Muzykantov V, Chacko AM, Pryma D, Dunn S, Coukos G.
  • Journal Title: Oncotarget. Volume: 5 Pages: 6994-7012
  • Peer Reviewed / Open Access
• [Journal Article] Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. (2014)
  • Author(s): Takeshima N, Matoda M, Abe M, Hirashima Y, Kai K, Nasu K, Takano M, Furuya K, Sato S, Itamochi H, Tsubamoto H, Hasegawa K, Terao K, Otsuki T, Kuritani K, Ito K.
  • Journal Title: Support Care Cancer. Volume: 22 Issue: 11 Pages: 2891-8
  • DOI: 10.1007/s00520-014-2280-6
  • Peer Reviewed
• [Journal Article] Effect of Lymphovascular Space Invasion on (2014)
  • Author(s): Koji Matsuo, Kiyoshi Yoshino, Kosuke Hiramatsu, Chiaki Banzai, Kosei Hasegawa, Masanori Yasuda, Masato Nishimura, Todd B. Sheridan, Yuji Ikeda, Yasuhiko Shiki, Seiji Mabuchi, Takayuki Enomoto, Tadashi Kimura, Keiichi Fujiwara, Lynda D. Roman, and Anil K. Sood
  • Journal Title: Obstet Gynecol Volume: 123 Issue: 5 Pages: 957-65
  • DOI: 10.1097/aog.0000000000000240
  • Peer Reviewed
• [Journal Article] 子宮頸がんに対するbevacizumabの第III相試験 (2014)
  • Author(s): 長谷川幸清、池田悠至、藤原恵一
  • Journal Title: 腫瘍内科 Volume: 13 Pages: 311-317
• [Journal Article] Antibody-Based Tumor Vascular Theranostics Targeting the Human Endosialin/TEM1 In Vivo. (2014)
  • Author(s): Li C, Chacko AM, Hu J, Hasegawa K, Swails J, Grasso L, El-Deiry WS, Nicolaides N, Muzykantov VR, Divgi CR, Coukos G.
  • Journal Title: Cancer Biol Ther. Volume: 15 Issue: 4 Pages: 443-51
  • DOI: 10.4161/cbt.27825
  • Peer Reviewed
• [Journal Article] Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. (2014)
  • Author(s): Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK.
  • Journal Title: Gynecol Oncol. Volume: Epubのため未 Issue: 3 Pages: 473-479
  • DOI: 10.1016/j.ygyno.2014.03.563
  • Peer Reviewed
• [Journal Article] がん免疫療法の最前線～卵巣癌に対する特異的癌免疫療法 (2014)
  • Author(s): 長谷川幸清、黒崎亮、藤原恵一
  • Journal Title: 産科と婦人科 Volume: 81 Pages: 172-177
• [Journal Article] Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. (2013)
  • Author(s): Fujiwara K, Nagao S, Aotani E, Hasegawa K.
  • Journal Title: Expert Opin Pharmacother. Volume: 14 Issue: 13 Pages: 1797-806
  • DOI: 10.1517/14656566.2013.820705
  • Peer Reviewed
• [Journal Article] Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed? (2013)
  • Author(s): Fujiwara K, Kurosaki A, Hasegawa K.
  • Journal Title: Curr Oncol Rep. Volume: 15 Issue: 3 Pages: 197-200
  • DOI: 10.1007/s11912-013-0313-9
  • Peer Reviewed
• [Journal Article] Estrogen-producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases. (2012)
  • Author(s): Katoh T, Yasuda M, Hasegawa K, Kozawa E, Maniwa J, Sasano H.
  • Journal Title: Diagn Pathol. Volume: 28 Issue: 1 Pages: 164-164
  • DOI: 10.1186/1746-1596-7-164
  • Peer Reviewed
• [Journal Article] Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma : A Feasibility Study (2012)
  • Author(s): Shoji Nagao
  • Journal Title: International Journal of Gynecological Cancer Volume: 22 Issue: 1 Pages: 70-75
  • DOI: 10.1097/igc.0b013e318234f927
  • Peer Reviewed
• [Journal Article] 子宮肉腫の臨床像と治療 (2012)
  • Author(s): 長谷川幸清
  • Journal Title: 日本婦人か病理学会誌 Volume: 3 Pages: 57-61
• [Presentation] 婦人科がんに対する維持化学療法のエビデンス構築に向けて (2014)
  • Author(s): 長谷川幸清
  • Organizer: 第５６回日本婦人科腫瘍学会学術講演会
  • Place of Presentation: 宇都宮
  • Year and Date: 2014-07-17 – 2014-07-19
  • Invited
• [Presentation] The use of an engineered sendai virus in urokinase-type plasminogen activator targeted therapy of ovarian cancer (2012)
  • Author(s): Kosei Hasegawa, Tatsuya Hanaoka, Akira Kurosaki, Keiichi Fujiwara
  • Organizer: 71th Japanese Cancer Association,
  • Place of Presentation: Sapporo
• [Presentation] Soluble MUC1 as a Biomarker for Epithelial Ovarian Cancer (2012)
  • Author(s): K. Hasegawa, T. Hanaoka, A. Kurosaki, A. Miyara, K. Abe, T. Kawamura, T. Sekino, T. Kato, M. Yasuda, K. Fujiwara
  • Organizer: 14th Biennial Meeting of the International Gynecologic Cancer Society,
  • Place of Presentation: Vancouver, Canada
• [Presentation] Redirected antitumor activity of an engineered Sendai virus vector in ovarian cancer cells
  • Author(s): K. Hasegawa, A. Miyara, T. Hanaoka, A. Kurosaki, Y. Ueda, M. Inoue2 M. Hasegawa and K. Fujiwara
  • Organizer: AACR/JCA 2013
  • Place of Presentation: Maui, USA
• [Presentation] Soluble folate receptor alpha as a biomarker for epithelial ovarian cancer
  • Author(s): Kosei Hasegawa, Akira Kurosaki, Tetsuo Sekino, Keiichi Fujiwara
  • Organizer: 72th Japanese Cancer Association
  • Place of Presentation: Yokohama
  • Invited
• [Remarks] 埼玉医科大学国際医療センター婦人科腫瘍科
  • URL: http://www.saitama-med.ac.jp/kokusai/fujinshuyo/research/index.html
• [Remarks] 埼玉医科大学国際医療センター 婦人科腫瘍科
  • URL: http://www.saitama-med.ac.jp/kokusai/fujinshuyo/research/index.html
• [Remarks] 埼玉医科大学国際医療センター 婦人科腫瘍科
  • URL: http://www.saitama-med.ac.jp/kokusai/fujinshuyo/research/index.html